Term ends Sep 9, 2034 · High confidence
20-year base term ends Sep 9, 2034
Held by Bioversys AG
Filed Oct 18, 2018 as application 16/163,822 · Granted Oct 27, 2020
Base term, 20 years from filing
Today
2014
2034
Clock starts
Sep 9, 2014
Sep 9, 2014
Term ends
Sep 9, 2034
Sep 9, 2034
Granted
Oct 27, 2020
Oct 27, 2020
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 9, 2014, when application PCT/US2014/054869, the earliest non-provisional in its chain, was filed (this one was filed Oct 18, 2018) | Sep 9, 2034 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Sep 9, 2034 | High confidence |
This family
| US 10,106,543 | Lapsed on the fee record Oct 2026 | Oct 2026 |
| US 10,815,238 | this patent Sep 2034 | Sep 2034 |
2 of 3 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 5, 2018 Reel 47680, frame 759 | Melinta Therapeutics, Inc.; Rempex Pharmaceuticals, Inc.; Cempra Pharmaceuticals, Inc.; Melinta Subsidiary Corp. | Cortland Capital Market Services LLC, as Agent | Security Interest |
| Apr 2, 2019 Reel 48764, frame 840 | Kanyo, Zoltan F.; Bhattacharjee, Ashoke; Duffy, Erin M.; Marra, Andrea | Melinta Therapeutics, Inc. | Assignment of Assignor's Interest |
| Apr 11, 2019 Reel 48875, frame 750 | Cortland Capital Market Services LLC, as Agent | Melinta Therapeutics, Inc. | Release of Security Interest |
| Aug 22, 2019 Reel 50128, frame 253 | Melinta Therapeutics, Inc.; Melinta Subsidiary Corp. | Bioversys AG | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Sep 2034
Term ends Sep 9, 2034. Maintenance fees still fall due before then
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2020 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.